Last updated on January 2019

Treat-to-target With Secukinumab in Axial Spondyloarthritis


Brief description of study

A study of axSpA and AS receiving Secukinumab in a treat-to-target strategy.

Detailed Study Description

Comparison of reductions in MRI inflammation in the sacroiliac joints and spine from week 16 to 24 in patients who at week 16 are in ASDAS remission (i.e. continue sc. secukinumab 150 mg monthly) vs. not in ASDAS remission (i.e. increase sc. secukinumab 300 mg monthly). ASDAS remission is defined as ASDAS inactive disease i.e. ASDAS<1.3.

Clinical Study Identifier: NCT03639740

Find a site near you

Start Over